Leaders in Pharmaceutical Business Intelligence (LPBI) Group

About 4.4% people out of diagnosed atrial fibrillation population are treated using ablation technology in the U.S., Europe, and Japan combined. The atrial fibrillation population treated with ablation is expected to grow with a double digit rate in these regions. The increasing prevalence of atrial fibrillation and advancement in the ablation technologies drive the use of ablation products in the treatment of atrial fibrillation.

The European Society of Cardiology guidelines recommend use of surgical and catheter ablation procedures for the treatment of atrial fibrillation, if anti-arrhythmic drug therapy results are inadequate. Further, guidelines recommend using surgical ablation for the treatment of patients failing catheter ablation.

This market is segmented, on the basis of surgical procedures, into catheter ablation and surgical ablation. Catheter ablation procedures hold the maximum share in this market and are expected to grow with the highest CAGR during forecast period of 2015 to 2020.

The geographical segmentation includes North America, Europe, Asia-Pacific and RoW. North America holds the largest share in this market, both in terms of number of procedures and revenue. However, Asia-Pacific is expected to witness the highest growth rate owing to the presence of a large patient population, growing medical tourism, and high focus of global market players on emerging Asia-Pacific countries such as China and India.

Major Players in AF Surgery Market are

Biosense Webster, Inc.
St. Jude Medical, Inc.
Medtronic, Inc.
Boston Scientific Corporation
Articure, Inc.
Cardiofocus, Inc.